Printer Friendly

Company Licenses Universal Donor Adult Stem Cell Product For CTE, Traumatic Brain Injury.

OCEANSIDE, Calif., Dec 10, 2018 -- Therapeutic Solutions International, Inc., (OTC: TSOI) has signed an agreement with Jadi Cell LLC to license the Jadi Cell universal donor adult stem cell (U.S. Patent No. 9,803,176 B2) for use in chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI).

The Jadi Cell product, comprising mesenchymal stem cells, produces higher levels of therapeutic factors compared to other stem cells.

The cells have demonstrated safety in animal models and pilot human trials.

The product is generated from umbilical cords, medical waste that is available cheaply in large quantities

Chronic traumatic encephalopathy (CTE) is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players.

The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia.

CTE is characterized by brain atrophy, reduced mass of frontal and temporal cortices, and medial temporal lobe.


COPYRIGHT 2018 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Technology Licensing
Publication:Stem Cell Research News
Date:Dec 17, 2018
Previous Article:The Source Of Stem Cells Points To Two Proteins.
Next Article:Companies Expand Cell Therapy Collaboration To Pursue CRISPR/Cas9-based Genome Editing.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |